journal article·2017-03

The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response

Emad I. Wafa, Sean M. Geary, Jonathan T. Goodman, Balaji Narasimhan, Aliasger K. Salem

Acta Biomaterialia· Volume 50
Publisher page

Abstract

The goal of this research was to study the effect of polyanhydride chemistry on the immune response induced by a prophylactic cancer vaccine based on biodegradable polyanhydride particles. To achieve this goal, different compositions of polyanhydride copolymers based on 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-bis-(p-carboxyphenoxy)-hexane (CPH), and sebacic anhydride (SA) were synthesized by melt polycondensation, and polyanhydride copolymer particles encapsulating a model antigen, ovalbumin (OVA), were then synthesized using a double emulsion solvent evaporation technique. The ability of three different compositions of polyanhydride copolymers (50:50 CPTEG:CPH, 20:80 CPTEG:CPH, and 20:80 CPH:SA) encapsulating OVA to elicit immune responses was investigated. In addition, the impact of unmethylated oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODN), an immunological adjuvant, on the immune response was also studied. The immune response to cancer vaccines was measured after treatment of C57BL/6J mice with two subcutaneous injections, seven days apart, of 50μg OVA encapsulated in particles composed of different polyanhydride copolymers with or without 25μg CpG ODN. In vivo studies showed that 20:80 CPTEG:CPH particles encapsulating OVA significantly stimulated the highest level of CD8+ T lymphocytes, generated the highest serum titers of OVA-specific IgG antibodies, and provided longer protection against tumor challenge with an OVA-expressing thymoma cell line in comparison to formulations made from other polyanhydride copolymers. The results also revealed that vaccination with CpG ODN along with polyanhydride particles encapsulating OVA did not enhance the immunogenicity of OVA. These results accentuate the crucial role of the copolymer composition of polyanhydrides in stimulating the immune response and provide important insights on rationally designing efficacious cancer vaccines. Statement of significance Compared to soluble cancer vaccine formulations, tumor antigens encapsulated in biodegradable polymeric particles have been shown to sustain antigen release and provide long-term protection against tumor challenge by improving the immune response towards the antigen. Treatment of mice with cancer vaccines based on different polyanhydride copolymers encapsulating OVA resulted in stimulation of tumor-specific immune responses with different magnitudes. This clearly indicates that polyanhydride chemistry plays a substantial role in stimulating the immune response. Vaccination with 20:80 CPTEG:CPH/OVA, the most hydrophobic formulation, stimulated the strongest cellular and humoral immune responses and provided the longest survival outcome without adding any other adjuvant. The most important finding in this study is that the copolymer composition of polyanhydride particle-based vaccines can have a direct effect on the magnitude of the antitumor immune response and should be selected carefully in order to achieve optimal cancer vaccine efficacy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (69)

Show source-provided references
1. Cancer vaccines10.1136/bmj.h988 ↗
2. 2015
3. 2016
4. Bonavida · 2013
5. Geinitz · 2014
6. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic10.1158/2326-6066.CIR-14-0110 ↗
7. Therapeutic cancer vaccines: past, present, and future10.1016/B978-0-12-407190-2.00007-1 ↗
8. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer
9. Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases10.1080/21645515.2015.1009345 ↗
10. Applying biodegradable particles to enhance cancer vaccine efficacy10.1007/s12026-014-8537-9 ↗
11. Novel approaches to pediatric vaccine delivery10.1016/j.addr.2005.12.002 ↗
12. Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses10.4161/hv.26136 ↗
13. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns10.1038/nri2868 ↗
14. Production of adjuvant-loaded biodegradable particles for use in cancer vaccines
15. A prolonged immune response to antigen delivered in poly (epsilon-caprolactone) microparticles10.1046/j.1440-1711.2003.01155.x ↗
16. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity10.1016/j.vaccine.2008.07.035 ↗
17. A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.410.1016/j.vaccine.2003.10.035 ↗
18. Biodegradable particles as vaccine delivery systems: size matters10.1208/s12248-012-9418-6 ↗
19. Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
20. Polyanhydride nanovaccine platform enhances antigen-specific cytotoxic T cell responses10.1142/S2339547814500162 ↗
21. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems10.1016/j.jconrel.2015.09.002 ↗
22. Matijević · 2011
23. Polyanhydride degradation and erosion10.1016/S0169-409X(02)00051-0 ↗
24. Toxicity, biodegradation and elimination of polyanhydrides10.1016/S0169-409X(02)00052-2 ↗
25. Role of polyanhydrides as localized drug carriers10.1016/j.jconrel.2004.12.021 ↗
26. Lee · 2007
27. Polyanhydrides: an overview10.1016/S0169-409X(02)00050-9 ↗
28. Amphiphilic polyanhydrides for protein stabilization and release10.1016/j.biomaterials.2006.08.047 ↗
29. High-throughput analysis of protein stability in polyanhydride nanoparticles10.1016/j.actbio.2010.04.004 ↗
30. Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens10.1016/j.actbio.2010.01.040 ↗
31. Effect of polymer chemistry and fabrication method on protein release and stability from polyanhydride microspheres10.1002/jbm.b.31478 ↗
32. Protein stability in the presence of polymer degradation products: consequences for controlled release formulations10.1016/j.biomaterials.2006.01.054 ↗
33. Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells10.1080/09205063.2014.940243 ↗
34. Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles10.1002/jbm.a.35086 ↗
35. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles10.1016/j.actbio.2013.06.006 ↗
36. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism10.1002/jbm.a.30545 ↗
37. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation10.1016/j.actbio.2011.03.023 ↗
38. Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation10.1128/CVI.00164-10 ↗
39. Polyanhydride nanovaccines induce germinal center B cell formation and sustained serum antibody responses10.1166/jbn.2016.2242 ↗
40. Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours10.1002/adhm.201300525 ↗
41. A systems approach to designing next generation vaccines: combining alpha-galactose modified antigens with nanoparticle platforms10.1038/srep03775 ↗
42. Functionalization of polyanhydride microparticles with di-mannose influences uptake by and intracellular fate within dendritic cells10.1016/j.actbio.2013.06.024 ↗
43. Single immunization with a suboptimal antigen dose encapsulated into polyanhydride microparticles promotes high titer and avid antibody responses10.1002/jbm.b.32820 ↗
44. Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants10.1038/srep00198 ↗
45. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants10.1016/j.biomaterials.2011.05.063 ↗
46. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases10.1371/journal.pone.0017642 ↗
47. The simultaneous effect of polymer chemistry and device geometry on the in vitro activation of murine dendritic cells10.1016/j.biomaterials.2009.05.069 ↗
48. Emulsifying properties of ovalbumin in mixtures with sulphated polysaccharides: effects of pH, ionic strength, heat and high-pressure treatment10.1002/1097-0010(200006)80:8<1219::AID-JSFA626>3.0.CO;2-W ↗
49. CpG oligodeoxynucleotides as immunotherapy in cancer10.1016/j.uct.2007.11.003 ↗
50. DNA-polymer conjugates for immune stimulation through Toll-like receptor 9 mediated pathways10.1016/j.actbio.2013.11.022 ↗
51. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles10.1016/j.actbio.2012.11.001 ↗
52. Distinct modulatory effects of LPS and CpG on IL-18-dependent IFN-gamma synthesis10.4049/jimmunol.172.3.1754 ↗
53. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery10.1016/S0142-9612(02)00181-3 ↗
54. Fabrication, characterization and in vitro evaluation of poly(D, L-lactide-co-glycolide) microparticles loaded with polyamidoamine-plasmid DNA dendriplexes for applications in nonviral gene delivery10.1002/jps.21840 ↗
55. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine10.1002/ijc.22873 ↗
56. Synthesis and characterization of novel polyanhydrides with tailored erosion mechanisms10.1002/jbm.a.30510 ↗
57. Preparation and degradation behavior of polyanhydrides nanoparticles10.1002/jbm.b.30854 ↗
58. Mechanistic relationships between polymer microstructure and drug release kinetics in bioerodible polyanhydrides10.1016/S0168-3659(02)00125-6 ↗
59. Protein adsorption on biodegradable polyanhydride microparticles10.1002/jbm.a.32815 ↗
60. Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation10.1016/j.jconrel.2012.11.015 ↗
61. Criteria impacting the cellular uptake of nanoparticles: a study emphasizing polymer type and surfactant effects10.1016/j.actbio.2011.07.033 ↗
62. Understanding biophysicochemical interactions at the nano-bio interface10.1038/nmat2442 ↗
63. Nanocarriers’ entry into the cell: relevance to drug delivery10.1007/s00018-009-0053-z ↗
64. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy10.1016/j.addr.2009.03.009 ↗
65. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles10.1016/j.ijpharm.2005.10.010 ↗
66. Nanoparticle hydrophobicity dictates immune response10.1021/ja2108905 ↗
67. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants10.1016/S0378-5173(02)00342-3 ↗
68. Effect of nanovaccine chemistry on humoral immune response kinetics and maturation10.1039/C4NR03724C ↗
69. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles10.1097/CJI.0b013e31802fd8c6 ↗